
Children and young people who have previously participated in clinical trials of migraine drug Vyepti have now been offered the chance to remain in treatment for a longer period.
Lundbeck is starting a trial where 610 people aged between 6 and 17 will receive quarterly infusions of Vyepti, in either a 100 or 300 mg dose. The aim is to investigate the long-term safety profile of using Vyepti over a longer period, Lundbeck writes in the study description on ClinicalTrials.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app